| A1048 |
Etesevimab
Featured
|
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody. |
|
| A1049 |
Tixagevimab
Featured
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor. |
|
| A1050 |
Regdanvimab
Featured
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19. |
|
| A1051 |
Cilgavimab
Featured
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection. |
|
| A1052 |
Romlusevimab
Featured
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). |
|
| A1053 |
Larcaviximab
Featured
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody. |
|
| A1054 |
Porgaviximab
Featured
|
Porgaviximab is a monoclonal antibody that can be used Ebola infection research. |
|
| A1055 |
Cosfroviximab
Featured
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP). |
|
| A1056 |
Odesivimab
Featured
|
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection. |
|
| A1057 |
Anti-IAV Reference Antibody
Featured
|
|
|
| A1058 |
Navivumab
Featured
|
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2. |
|
| A1059 |
Atoltivimab
Featured
|
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection. |
|
| A1060 |
Muromonab
Featured
|
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection. |
|
| DC67212 |
Acuitas Lipid III-25
Featured
|
Acuitas Lipid III-25 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent US 10,166,298 B2. It is an analgous of ALC-0315, showing higher activity than ALC-0315. |
|
| DC67213 |
Acuitas II-10
Featured
|
Acuitas II-10 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent WO2016176330A1 |
|
| DC67214 |
Acuitas II-12
Featured
|
Acuitas II-12 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent WO2016176330A1 |
|
| DC67215 |
Acuitas Lipid III-7
Featured
|
Acuitas Lipid III-7 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent US 10,166,298 B2. |
|
| DC67216 |
Moderna Lipid 26（compound 26）
Featured
|
|
|
| DC67217 |
Moderna Lipid 46
Featured
|
Moderna Lipid compound 46 is an novel ionizable amine lipid used for mRNA delivery from Moderna patent WO2017049245A2 |
|
| DC67218 |
Moderna Lipid compound 182
Featured
|
Moderna Lipid Compound 182 is a novel ionizable amine lipid developed by Moderna for the delivery of mRNA-based therapeutics. This lipid is part of Moderna's proprietary lipid nanoparticle (LNP) delivery platform, which is designed to encapsulate and protect mRNA, facilitate its cellular uptake, and enable efficient intracellular release. The ionizable nature of Lipid Compound 182 allows it to interact with mRNA at low pH (during LNP formulation) and release the payload in the neutral pH environment of the cytoplasm, making it a critical component of Moderna's mRNA delivery system. |
|
| DC67219 |
Lipid 29 analogue-3
Featured
|
Lipid 29 analogue-3 is an ionizable lipid designed for the delivery of RNA-based therapeutics, such as mRNA or siRNA. |
|
| DC60732 |
VUF10166
Featured
|
VUF10166 is a potent and high-affinity 5-HT3 receptor antagonist, with Ki values of 0.04 nM (5-HT3A) and 22 nM (5-HT3AB). VUF10166 inhibits 5-HT-induced responses at 5-HT3A and 5-HT3AB receptors at nanomolar concentrations. At 5-HT3 receptor, VUF10166 at higher concentrations also acts as a partial agonist, with an EC50 of 5.2 μM. |
|
| DC60733 |
F-1
Featured
|
F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. |
|
| DC60734 |
MMBC
Featured
|
MMBC is a sulfhydryl-sensitive fluorophore. |
|
| DC60735 |
ATP synthase inhibitor 1
Featured
|
ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels. |
|
| DC60736 |
Mebeverine alcohol
Featured
|
Mebeverine alcohol is a metabolite of Mebeverine, which is a musculotropic antispasmodic drug. |
|
| DC60737 |
Sunitinib
Featured
|
|
|
| DC67220 |
Acuitas Lipid II-10
Featured
|
|
|
| DC60738 |
ROCK inhibitor-2
Featured
|
ROCK inhibitor-2 (compound 6) is a selective dual inhibitor of ROCK1 and ROCK2, with IC50 values of 160 nM and 21 nM, respectively. ROCK inhibitor-2 inhibits pMYPT1 with IC50 of 75 nM. |
|
| DC60739 |
WAY-213613 hydrochloride
Featured
|
WAY-213613 (hydrochloride) is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC50 value of 85 nM. WAY-213613 can be used for the research of central nervous system. |
|
